medroxyprogesterone acetate has been researched along with Osteosarcoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bunce, CM; Ellington, MA; Johnson, WE; Khanim, FL; MacKay, HL; Sheard, JJ; Snow, MD; Southam, AD | 1 |
1 other study(ies) available for medroxyprogesterone acetate and Osteosarcoma
Article | Year |
---|---|
Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells.
Topics: Bezafibrate; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Repositioning; Drug Therapy, Combination; Fatty Acid Synthases; Humans; Medroxyprogesterone Acetate; Mesenchymal Stem Cells; Osteosarcoma; Stearoyl-CoA Desaturase; Up-Regulation; Valproic Acid | 2021 |